Narcolepsy Therapeutics Market

SKU: DMPH2050 | Last Updated On: Nov 29 2021 | No. of Pages: 180 | Available Formats

> Global Narcolepsy Therapeutics Market Expected to reach a high CAGR of 11.3% by 2028: DataM Intelligence

Global Narcolepsy Therapeutics Market is segmented By Disease Type (Daytime Extreme Sleepiness, Cataplexy, Others), By Therapeutic Type (Sodium Oxybate, Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The Global "Narcolepsy Therapeutics Market" is expected to grow at a high CAGR of 11.3% during the forecasting period (2021-2028).

Narcolepsy is a rare sleep disorder associated with uncontrollable sleepiness and frequent daytime sleeping. The condition is characterized by several symptoms, including excessive daytime sleepiness (EDS), cataplexy, automatic behaviors, hallucinations, and sleep paralysis. Narcolepsy has no cure, but drug therapies and lifestyle changes can often help improve symptoms.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The global narcolepsy therapeutics market is growing due to several factors such as the rising prevalence of narcolepsy, growing narcolepsy awareness programs, increasing research & development for new drugs and treatment for narcolepsy.

The narcolepsy affects 0.03 to 0.16% of the general population with an incidence of 1/2,000 globally. The American Academy of Sleep Medicine's International Classification of Sleep Disorders has classified two forms of narcolepsy: narcolepsy with cataplexy (also called narcolepsy type 1 (NT1)) and narcolepsy without cataplexy (also known as narcolepsy type 2 (NT2)). The NT1 is most commonly caused by a deficiency of central nervous system (CNS) hypocretin (hcrt also called orexin) in the hypothalamus. The prevalence of narcolepsy type 1 is 25 to 50 per 100,000 people and 20 to 34 per 100,000 people for narcolepsy type 2.

The robust pipeline portfolio also drives this growth of the market. There are currently few approved therapies available for narcolepsy. Some of the approved drugs for narcolepsy are Xyrem (sodium oxybate), amphetamine, Nuvigil (armodafinil), Provigil (modafinil), and methylphenidate. The majority of the drugs are also used off-label for narcolepsy, including stimulants, depressants, and antidepressants. In October 2018, the Food and Drug Administration has cleared Xyrem (sodium oxybate) oral solution to treat cataplexy and excessive daytime sleepiness in patients ages 7-17 with narcolepsy. The two highest-selling drugs are expected to be Avadel’s/ Sodium oxybate ER and Jazz Pharmaceutical’s/JZP-258, which both address some of the unmet needs in the market.

However, market growth is hindered by the adverse effects and risks associated with narcolepsy drugs and delayed diagnosis.

Market Segmentation

On the basis of disease type, the narcolepsy therapeutics market is segmented into daytime extreme sleepiness (DES), cataplexy, and others. Among these, daytime extreme sleepiness (DES) accounted for the largest market share in 2018, due to the rising prevalence of narcolepsy and other sleep disorders. Daytime extreme sleepiness is one of the most common sleep-related patient symptoms affecting an estimated 20% of the population. Obstructive sleep apnea is a particularly significant cause of excessive daytime sleepiness. An estimated 26 to 32% of adults are at risk of or have obstructive sleep apnea, and the prevalence is expected to increase during the forecast period. About 20% of adults in the United States report a level of daytime sleepiness sufficient to interfere with daily activities, and excessive daytime sleepiness is the leading symptom of patients presenting to sleep clinics. On the other hand, the cataplexy segment is expected to grow at the fastest CAGR during the forecast period (2020-2027), as patients suffering from cataplexy tend to lose muscle control and the majority of narcolepsy patients have this symptom. Cataplexy is a common type of narcolepsy disorder, which affects nearly around 0.02% to 0.05% of the population globally.

By therapeutics type, the narcolepsy Therapeutics market is segmented into central nervous system stimulants, sodium oxybate, triTheelective serotonin reuptake inhibitors, and others. The sodium oxybate segment held the largest market share in 2018, as these drugs are highly effective to treat day by therapeutics type time extreme sleepiness and cataplexy. Sodium oxybate (Xyrem) is the sodium salt of gamma-hydroxybutyrate (GHB), a naturally occurring substance in the brain. Sodium oxybate is quite different from the other medications used to treat narcolepsy as it is a sedating liquid taken at bedtime instead of a usual pill taken during the day. Its effects last only a few hours, a second dose is taken three to four hours later. These two doses produce deep sleep through much of the night, and after several weeks of regular use, sodium oxybate usually improves daytime sleepiness and cataplexy. On the other hand, the selective serotonin reuptake inhibitor segment is expected to grow at the fastest CAGR during the forecast period (2020-2027), due to rising R&D activities for the development of these types of drugs by the major players in the market.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

North America holds the dominant market share for narcolepsy therapeutics in 2018, and it is expected to maintain the growth over the forecast period, due to the factors, such as rising prevalence of narcolepsy and other sleep disorders, robust pipeline product for the treatment of narcolepsy by manufactures, and rising awareness towards this sleep disorder. In the United States, around 1 among the 2000 patients are affected by narcolepsy disorder. The prevalence in North America is around 0.07%. Thus, the growing measures in therapeutics for the diagnosis and treatment of narcolepsy lead to the growth of the market in the North American region during the forecast period (2020-2027). For instance, on August 15th, 2019, the US FDA has app north America region's growth sciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Pitolisant is the first and only treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the US Drug Enforcement Administration. Pitolisant is expected to be commercially available to healthcare professionals and appropriate patients in the US in the fourth quarter of 2019.

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

The narcolepsy therapeutics market is highly competitive with the presence of a large number of players, including Jazz Pharmaceutical plc, Arena Pharmaceutical, Inc., Ligand Pharmaceuticals Inc., Bioprojet Pharma, Novartis, Teva Pharmaceutical Industries Ltd., Shinogi Inc., Takeda Pharmaceutical Company, Addrenex Pharmaceuticals, , among others hire Plc.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the narcolepsy therapeutics market globally. For instance,

In March 2019, Jazz Pharmaceuticals plc received the U.S. FDA approval for Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

In January 2018, Glenmark Pharmaceutical entered into a license agreement with Ligand Pharmaceuticals to use the full range of OmniAb platform to discover mono multispecific antibodies.

Why Purchase the Report?

  • Visualize the composition of the narcolepsy therapeutics market segmentation by disease type and therapeutics type highlighting the key commercial assets and players.
  • Identify commercial opportunities in the narcolepsy therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of narcolepsy therapeutics market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The Global Narcolepsy Therapeutics Market report would provide access to an approx. 53 market data tables, 44 figures, and 210 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Trending Topics

Warts Therapeutics Market

Protein Therapeutics Market

 

Table of Contents

  1. Narcolepsy Therapeutics Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Narcolepsy Therapeutics Market – Market Definition and Overview

  3. Narcolepsy Therapeutics Market – Executive Summary

    1. Market Snippet by Disease Type
    2. Market Snippet by Therapeutic Type
    3. Market Snippet by Region
  4. Narcolepsy Therapeutics Market – Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Rising Prevalence of Narcolepsy
        2. Increasing awareness programs and services regarding Narcolepsy
      2. Restraints
        1. Adverse effects and risks related to narcolepsy drugs
      3. Opportunity
      4. Impact Analysis
  5. Narcolepsy Therapeutics Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Epidemiology
    3. Regulatory Analysis
    4. Reimbursement Scenario
    5. Pipeline Analysis
    6. Supply Chain Analysis
    7. Pricing Analysis
    8. Unmet Needs
  6. Narcolepsy Therapeutics Market – By Disease Type

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    3. Market Attractiveness Index, By Disease Type Segment
      1. Daytime Extreme Sleepiness (DES)*
        1. Introduction
        2.  Market Size Analysis and Y-o-Y Growth Analysis (%)
      2. Cataplexy
      3. Others
  7. Narcolepsy Therapeutics Market – By Therapeutic Type

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Type Segment
    3. Market Attractiveness Index, By Therapeutic Type Segment
      1. Sodium Oxybate*
        1. Introduction
        2.  Market Size Analysis and Y-o-Y Growth Analysis (%)
      2. Central Nervous System Stimulants
      3. Tricyclic Antidepressants
      4. Selective Serotonin Reuptake Inhibitor
      5. Others
  8. Narcolepsy Therapeutics Market – By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutic Type
  9. Narcolepsy Therapeutics Market – Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  10. Narcolepsy Therapeutics Market- Company Profiles

    1. Jazz Pharmaceutical Plc*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Arena Pharmaceutical, Inc.
    3. Ligand Pharmaceuticals Inc.
    4. Bioprojet Pharma
    5. Novartis AG
    6. Teva Pharmaceutical Industries Ltd.
    7. Shinogi Inc.
    8. Takeda Pharmaceutical Company
    9. Addrenex Pharmaceuticals
    10. Shire Plc (** List not exhaustive)

  11. Narcolepsy Therapeutics Market – Premium Insights

  12. Narcolepsy Therapeutics Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

 

List of Tables & Figures

List of Tables
Table 1 Global Narcolepsy Therapeutics Market Value, By Disease Type, 2018,2022 & 2028 ($ Million)
Table 2 Global Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2018,2022 & 2028 ($ Million)
Table 3 Global Narcolepsy Therapeutics Market Value, By Region, 2018,2022 & 2028 ($ Million)
Table 4 Global Narcolepsy Therapeutics Market Value, By Disease Type, 2018,2022 & 2028 ($ Million)
Table 5 Global Narcolepsy Therapeutics Market Value, By Disease Type, 2017-2028 ($ Million)
Table 6 Global Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2018,2022 & 2028 ($ Million)
Table 7 Global Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2017-2028 ($ Million)
Table 8 Global Narcolepsy Therapeutics Market Value, By Region, 2018,2022 & 2028 ($ Million)
Table 9 Global Narcolepsy Therapeutics Market Value, By Region, 2017-2028 ($ Million)
Table 10 North America Narcolepsy Therapeutics Market Value, By Disease Type, 2017-2028 ($ Million)
Table 11 North America Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2017-2028 ($ Million)
Table 12 North America Narcolepsy Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 13 South America Narcolepsy Therapeutics Market Value, By Disease Type, 2017-2028 ($ Million)
Table 14 South America Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2017-2028 ($ Million)
Table 15 South America Narcolepsy Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 16 Europe Narcolepsy Therapeutics Market Value, By Disease Type, 2017-2028 ($ Million)
Table 17 Europe Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2017-2028 ($ Million)
Table 18 Europe Narcolepsy Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 19 Asia-Pacific Narcolepsy Therapeutics Market Value, By Disease Type, 2017-2028 ($ Million)
Table 20 Asia-Pacific Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2017-2028 ($ Million)
Table 21 Asia-Pacific Narcolepsy Therapeutics Market Value, By Country, 2017-2028 ($ Million)
Table 22 Middle East & Africa Narcolepsy Therapeutics Market Value, By Disease Type, 2017-2028 ($ Million)
Table 23 Middle East & Africa Narcolepsy Therapeutics Market Value, By Therapeutics Type, 2017-2028 ($ Million)
Table 24 Jazz Pharmaceutical plc: Overview
Table 25 Jazz Pharmaceutical plc: Product Portfolio
Table 26 Jazz Pharmaceutical plc: Key Developments
Table 27 Arena Pharmaceutical, inc.: Overview
Table 28 Arena Pharmaceutical, inc.: Product Portfolio
Table 29 Arena Pharmaceutical, inc.: Key Developments
Table 30 Ligand Pharmaceuticals Inc.: Overview
Table 31 Ligand Pharmaceuticals Inc.: Product Portfolio
Table 32 Ligand Pharmaceuticals Inc.: Key Developments
Table 33 Bioprojet Pharma: Overview
Table 34 Bioprojet Pharma: Product Portfolio
Table 35 Bioprojet Pharma: Key Developments
Table 36 Novartis AG: Overview
Table 37 Novartis AG: Product Portfolio
Table 38 Novartis AG: Key Developments
Table 39 Teva Pharmaceutical Industries Ltd.: Overview
Table 40 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 41 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 42 Shinogi Inc.: Overview
Table 43 Shinogi Inc.: Product Portfolio
Table 44 Shinogi Inc.: Key Developments
Table 45 Takeda Pharmaceutical Company: Overview
Table 46 Takeda Pharmaceutical Company: Product Portfolio
Table 47 Takeda Pharmaceutical Company: Key Developments
Table 48 Addrenex Pharmaceuticals: Overview
Table 49 Addrenex Pharmaceuticals: Product Portfolio
Table 50 Addrenex Pharmaceuticals: Key Developments
Table 51 Shire Plc: Overview
Table 52 Shire Plc: Product Portfolio
Table 53 Shire Plc: Key Developments

List of Figures
Figure 1 Global Narcolepsy Therapeutics Market Share, By Disease Type, 2018 & 2028 (%)
Figure 2 Global Narcolepsy Therapeutics Market Share, By Therapeutics Type, 2018 & 2028 (%)
Figure 3 Global Narcolepsy Therapeutics Market Share, By Region, 2018 & 2028 (%)
Figure 4 Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 5 Global Narcolepsy Therapeutics Market Y-o-Y Growth, By Disease Type, 2018-2028 (%)
Figure 6 Daytime Extreme Sleepiness (DES): Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 7 Cataplexia: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 8 Others: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 9 Global Narcolepsy Therapeutics Market Y-o-Y Growth, By Therapeutics Type, 2018-2028 (%)
Figure 10 Central Nervous System Stimulants: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 11 Sodium Oxybate: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 12 Tricyclic Antidepressants: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 13 Selective Serotonin Reuptake Inhibitor: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 14 Others: Global Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 15 Global Narcolepsy Therapeutics Market Y-o-Y Growth, By Region, 2018-2028 (%)
Figure 16 North America Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 17 North America Narcolepsy Therapeutics Market Share, By Disease Type, 2018 & 2028 (%)
Figure 18 North America Narcolepsy Therapeutics Market Share, By Therapeutics Type, 2018 & 2028 (%)
Figure 19 North America Narcolepsy Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 20 South America Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 21 South America Narcolepsy Therapeutics Market Share, By Disease Type, 2018 & 2028 (%)
Figure 22 South America Narcolepsy Therapeutics Market Share, By Therapeutics Type, 2018 & 2028 (%)
Figure 23 South America Narcolepsy Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 24 Europe Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 25 Europe Narcolepsy Therapeutics Market Share, By Disease Type, 2018 & 2028 (%)
Figure 26 Europe Narcolepsy Therapeutics Market Share, By Therapeutics Type, 2018 & 2028 (%)
Figure 27 Europe Narcolepsy Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 28 Asia-Pacific Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 29 Asia-Pacific Narcolepsy Therapeutics Market Share, By Disease Type, 2018 & 2028 (%)
Figure 30 Asia-Pacific Narcolepsy Therapeutics Market Share, By Therapeutics Type, 2018 & 2028 (%)
Figure 31 Asia-Pacific Narcolepsy Therapeutics Market Share, By Country, 2018 & 2028 (%)
Figure 32 Middle East & Africa Narcolepsy Therapeutics Market Value, 2017-2028 ($ Million)
Figure 33 Middle East & Africa Narcolepsy Therapeutics Market Share, By Disease Type, 2018 & 2028 (%)
Figure 34 Middle East & Africa Narcolepsy Therapeutics Market Share, By Therapeutics Type, 2018 & 2028 (%)
Figure 35 Jazz Pharmaceutical plc: Financials
Figure 36 Arena Pharmaceutical, inc.: Financials
Figure 37 Ligand Pharmaceuticals Inc.: Financials
Figure 38 Bioprojet Pharma: Financials
Figure 39 Novartis AG: Financials
Figure 40 Teva Pharmaceutical Industries Ltd.: Financials
Figure 41 Shinogi Inc.: Financials
Figure 42 Takeda Pharmaceutical Company: Financials
Figure 43 Addrenex Pharmaceuticals: Financials
Figure 44 Shire Plc: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest